This webinar was held on December 5, 2023, and provided an update on HIV cure-related research studies being conducted by the company AbbVie, including a review of results presented recently at the European AIDS Conference and plans for a new phase 2 trial investigating antibodies targeting the cell receptors PD-1 and α4β7 integrin in people with HIV.

Co-sponsored by TAG, the DARE and RID Collaboratory Community Advisory Boards, and HIV i-Base.

Presenters
Arlene Nugent
Scientific Director Specialty Pipeline
Global Medical Affairs
AbbVie

Dr. Ana Gabriela Pires Dos Santos
Medical Director
Clinical Development, Infectious Diseases
AbbVie